| __timestamp | AstraZeneca PLC | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 13324000000 | 91733000 |
| Thursday, January 1, 2015 | 11451000000 | 87644000 |
| Friday, January 1, 2016 | 9739000000 | 92365000 |
| Sunday, January 1, 2017 | 10543000000 | 85656000 |
| Monday, January 1, 2018 | 10362000000 | 88196000 |
| Tuesday, January 1, 2019 | 11848000000 | 89971000 |
| Wednesday, January 1, 2020 | 11693000000 | 93413000 |
| Friday, January 1, 2021 | 15680000000 | 91355000 |
| Saturday, January 1, 2022 | 18955000000 | 113676000 |
| Sunday, January 1, 2023 | 18025000000 | 198366000 |
| Monday, January 1, 2024 | 20532000000 | 218935000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical industry, understanding spending patterns is crucial for strategic planning. Over the past decade, AstraZeneca PLC and Taro Pharmaceutical Industries Ltd. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. AstraZeneca's SG&A expenses have surged by approximately 35% from 2014 to 2023, peaking in 2022. This reflects their aggressive market expansion and investment in new drug launches. In contrast, Taro's SG&A expenses have remained relatively stable, with a notable increase of about 140% in 2023, indicating a potential shift in their strategic focus. The data for 2024 is incomplete, suggesting ongoing developments. These insights highlight the contrasting strategies of a global giant and a niche player, offering a glimpse into their future trajectories. As the pharmaceutical landscape continues to shift, monitoring these patterns will be key for investors and industry analysts alike.
Cost Management Insights: SG&A Expenses for Johnson & Johnson and AstraZeneca PLC
Breaking Down SG&A Expenses: AbbVie Inc. vs AstraZeneca PLC
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Neurocrine Biosciences, Inc.
Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and United Therapeutics Corporation
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Insmed Incorporated
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and Pharming Group N.V.
Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and Alkermes plc
Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and HUTCHMED (China) Limited
Operational Costs Compared: SG&A Analysis of Dr. Reddy's Laboratories Limited and Taro Pharmaceutical Industries Ltd.
Blueprint Medicines Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Selling, General, and Administrative Costs: Ultragenyx Pharmaceutical Inc. vs Taro Pharmaceutical Industries Ltd.